Statements of Income
Performance by Subgroup and Segment
Bayer Links
Investor Relations
Management Report
Bayer HealthCare
Sales of the Bayer HealthCare subgroup rose by 3.3 percent in the third quarter of 2008, to €3,802 million (Q3 2007: €3,680 million). Adjusted for currency and portfolio changes, business was up by 6.1 percent. The Pharmaceuticals and Consumer Health segments both contributed to the increase.
Bayer HealthCare improved third-quarter EBITDA before special items by 6.8 percent to €1,018 million (Q3 2007: €953 million). Earnings growth was due mainly to the pleasing performance of the business and the synergies realized from the integration of Schering AG, Germany. These factors were partially offset by adverse shifts in currency parities and a substantial increase in the marketing expenses related to the expansion of our activities in emerging countries and to new product introductions. EBIT before special items improved from €644 million to €703 million. The special items totaling minus €160 million resulted primarily from charges in connection with the acquisition and integration of Schering AG and the market withdrawal of Vasovist®. EBIT advanced by a strong 44.8 percent to €543 million (Q3 2007: €375 million).
Bayer HealthCare improved third-quarter EBITDA before special items by 6.8 percent to €1,018 million (Q3 2007: €953 million). Earnings growth was due mainly to the pleasing performance of the business and the synergies realized from the integration of Schering AG, Germany. These factors were partially offset by adverse shifts in currency parities and a substantial increase in the marketing expenses related to the expansion of our activities in emerging countries and to new product introductions. EBIT before special items improved from €644 million to €703 million. The special items totaling minus €160 million resulted primarily from charges in connection with the acquisition and integration of Schering AG and the market withdrawal of Vasovist®. EBIT advanced by a strong 44.8 percent to €543 million (Q3 2007: €375 million).
Pharmaceuticals
Sales of the Pharmaceuticals segment increased by 2.6 percent in the third quarter of 2008, to €2,638 million (Q3 2007: €2,570 million). Adjusted for currency and portfolio effects, business expanded by 5.9 percent.
Sales of the Primary Care business unit were level with the same period of last year, at €742 million (Q3 2007: €743 million). On a currency-adjusted (Fx adj.) basis, business expanded by 3.1 percent. Particularly strong gains were recorded by Aspirin Cardio® (Fx adj. +15.8 percent) and Avalox®/Avelox® (Fx adj. +6.3 percent), especially in the Asia-Pacific region.
Women’s Healthcare saw sales rise by 6.8 percent to €709 million (Q3 2007: €664 million). Adjusted for shifts in exchange rates, business moved ahead 10.7 percent. The intrauterine contraceptive system Mirena® (Fx adj. +17.1 percent) and the oral contraceptives Yasmin®/YAZ®/Yasminelle® (Fx adj. +15.1 percent) were again particularly successful in the market. Even in the United States, sales of the YAZ® family as a whole recorded an increase despite the launch of a generic competitor for Yasmin®. In September 2008, we began the European market introduction of YAZ®, a low-dose contraceptive tablet.
Sales of the Diagnostic Imaging business unit rose by 1.6 percent in the third quarter of 2008, to €325 million (Q3 2007: €320 million). Adjusted for currency and portfolio effects, business expanded by 1.7 percent. Sales of our subsidiary Medrad advanced by €11 million to €104 million (Fx and portfolio adj. +3.3 percent). Sales of Ultravist® progressed particularly well (Fx adj. +10.1 percent), while business with Magnevist® showed another marked decline (Fx adj. -16.3 percent), due in part to the shift toward Gadovist® in Europe. The U.S. Food and Drug Administration (FDA) granted marketing authorization for Bayer’s contrast agent EOVIST® for magnetic resonance imaging of the liver.
The Specialized Therapeutics business unit saw sales rise by 9.2 percent to €344 million (Q3 2007: €315 million), or by 12.9 percent when adjusted for currency effects. The increase here was mainly attributable to our multiple sclerosis drug Betaferon®/Betaseron® (Fx adj. +15.2 percent).
In the Hematology/Cardiology business unit, sales declined by 8.0 percent to €243 million. On a currency- and portfolio-adjusted basis, sales were down by 3.3 percent. The positive performance of Kogenate® (Fx adj. +14.8 percent) did not fully offset the drop.
Sales of the Primary Care business unit were level with the same period of last year, at €742 million (Q3 2007: €743 million). On a currency-adjusted (Fx adj.) basis, business expanded by 3.1 percent. Particularly strong gains were recorded by Aspirin Cardio® (Fx adj. +15.8 percent) and Avalox®/Avelox® (Fx adj. +6.3 percent), especially in the Asia-Pacific region.
Women’s Healthcare saw sales rise by 6.8 percent to €709 million (Q3 2007: €664 million). Adjusted for shifts in exchange rates, business moved ahead 10.7 percent. The intrauterine contraceptive system Mirena® (Fx adj. +17.1 percent) and the oral contraceptives Yasmin®/YAZ®/Yasminelle® (Fx adj. +15.1 percent) were again particularly successful in the market. Even in the United States, sales of the YAZ® family as a whole recorded an increase despite the launch of a generic competitor for Yasmin®. In September 2008, we began the European market introduction of YAZ®, a low-dose contraceptive tablet.
Sales of the Diagnostic Imaging business unit rose by 1.6 percent in the third quarter of 2008, to €325 million (Q3 2007: €320 million). Adjusted for currency and portfolio effects, business expanded by 1.7 percent. Sales of our subsidiary Medrad advanced by €11 million to €104 million (Fx and portfolio adj. +3.3 percent). Sales of Ultravist® progressed particularly well (Fx adj. +10.1 percent), while business with Magnevist® showed another marked decline (Fx adj. -16.3 percent), due in part to the shift toward Gadovist® in Europe. The U.S. Food and Drug Administration (FDA) granted marketing authorization for Bayer’s contrast agent EOVIST® for magnetic resonance imaging of the liver.
The Specialized Therapeutics business unit saw sales rise by 9.2 percent to €344 million (Q3 2007: €315 million), or by 12.9 percent when adjusted for currency effects. The increase here was mainly attributable to our multiple sclerosis drug Betaferon®/Betaseron® (Fx adj. +15.2 percent).
In the Hematology/Cardiology business unit, sales declined by 8.0 percent to €243 million. On a currency- and portfolio-adjusted basis, sales were down by 3.3 percent. The positive performance of Kogenate® (Fx adj. +14.8 percent) did not fully offset the drop.
| Bayer HealthCare | 3rd Quarter 2007 | 3rd Quarter 2008 | Change | First Nine Months 2007 | First Nine Months 2008 | Change |
| € million | € million | % | € million | € million | % | |
| Sales | 3,680 | 3,802 | +3.3 | 11,007 | 11,267 | +2.4 |
| Pharmaceuticals | 2,570 | 2,638 | +2.6 | 7,648 | 7,836 | +2.5 |
| Consumer Health | 1,110 | 1,164 | +4.9 | 3,359 | 3,431 | +2.1 |
| Sales by Region | ||||||
| Europe | 1,540 | 1,588 | +3.1 | 4,602 | 4,753 | +3.3 |
| North America | 1,086 | 1,093 | +0.6 | 3,323 | 3,222 | -3.0 |
| Asia/Pacific | 514 | 561 | +9.1 | 1,503 | 1,632 | +8.6 |
| Latin America/Africa/ Middle East | 540 | 560 | +3.7 | 1,579 | 1,660 | +5.1 |
| EBITDA1 | 836 | 905 | +8.3 | 2,407 | 2,762 | +14.7 |
| Special items | (117) | (113) | (463) | (300) | ||
| EBITDA before special items2 | 953 | 1,018 | +6.8 | 2,870 | 3,062 | +6.7 |
| EBITDA margin before special items | 25.9% | 26.8% | 26.1% | 27.2% | ||
| EBIT1 | 375 | 543 | +44.8 | 1,291 | 1,619 | +25.4 |
| Special items | (269) | (160) | (617) | (386) | ||
| EBIT before special items2 | 644 | 703 | +9.2 | 1,908 | 2,005 | +5.1 |
| Gross cash flow1 | 708 | 799 | +12.9 | 1,810 | 2,142 | +18.3 |
| Net cash flow1 | 684 | 679 | -0.7 | 1,351 | 1,410 | +4.4 |
1 for definition see Bayer Group Key Data.
2 for definition see also Calculation of EBIT(DA) Before Special Items.
2 for definition see also Calculation of EBIT(DA) Before Special Items.
| Pharmaceuticals | 3rd Quarter 2007 | 3rd Quarter 2008 | Change | First Nine Months 2007 | First Nine Months 2008 | Change |
| € million | € million | % | € million | € million | % | |
| Sales | 2,570 | 2,638 | +2.6 | 7,648 | 7,836 | +2.5 |
| Primary Care | 743 | 742 | -0.1 | 2,282 | 2,254 | -1.2 |
| Women's Healthcare | 664 | 709 | +6.8 | 1,943 | 2,128 | +9.5 |
| Diagnostic Imaging (including Medrad) | 320 | 325 | +1.6 | 957 | 944 | -1.4 |
| Specialized Therapeutics | 315 | 344 | +9.2 | 928 | 1,000 | +7.8 |
| Hematology/Cardiology | 264 | 243 | -8.0 | 803 | 686 | -14.6 |
| Oncology | 203 | 215 | +5.9 | 550 | 639 | +16.2 |
| Dermatology (Intendis) | 61 | 60 | -1.6 | 185 | 185 | 0.0 |
| Sales by Region | ||||||
| Europe | 1,104 | 1,095 | -0.8 | 3,258 | 3,296 | +1.2 |
| North America | 704 | 714 | +1.4 | 2,153 | 2,126 | -1.3 |
| Asia/Pacific | 419 | 459 | +9.5 | 1,236 | 1,337 | +8.2 |
| Latin America/Africa/ Middle East | 343 | 370 | +7.9 | 1,001 | 1,077 | +7.6 |
| EBITDA1 | 598 | 630 | +5.4 | 1,674 | 2,016 | +20.4 |
| Special items | (117) | (108) | (463) | (260) | ||
| EBITDA before special items2 | 715 | 738 | +3.2 | 2,137 | 2,276 | +6.5 |
| EBITDA margin before special items | 27.8% | 28.0% | 27.9% | 29.0% | ||
| EBIT1 | 169 | 306 | +81.1 | 657 | 981 | +49.3 |
| Special items | (269) | (155) | (617) | (346) | ||
| EBIT before speciel items2 | 438 | 461 | +5.3 | 1,274 | 1,327 | +4.2 |
| Gross cash flow1 | 519 | 586 | +12.9 | 1,290 | 1,577 | +22.2 |
| Net cash flow1 | 464 | 496 | +6.9 | 945 | 989 | +4.7 |
1 for definition see Bayer Group Key Data.
2 for definition see also Calculation of EBIT(DA) Before Special Items.
2 for definition see also Calculation of EBIT(DA) Before Special Items.
In sales resulting from the worldwide suspension of marketing for Trasylol®. In the third quarter of 2008, we began marketing Xarelto® in Germany, the Netherlands and Canada. This novel anticoagulant, a once-daily tablet, can be used to prevent venous thromboembolism (VTE) in patients following hip or knee replacement surgery. In July 2008 our cooperation partner for Xarelto®, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., filed a registration application for Xarelto® with the U.S. Food and Drug Administration.
The Oncology business unit saw sales expand by 5.9 percent to €215 million (Q3 2007: €203 million). On a currency-adjusted basis the increase came to 9.4 percent, boosted by strong growth in sales of Nexavar® (Fx adj. +62.9 percent), which more than offset the sales decline in certain other products. In July 2008 the Chinese State Food and Drug Administration approved Nexavar® for the treatment of inoperable or metastasizing forms of liver cancer.
Sales from our Dermatology business (Intendis) in the third quarter were level with the prior-year quarter at €60 million, rising by 1.3 percent on a currency-adjusted basis.
In September 2008 we acquired DIREVO Biotech AG, Cologne, Germany. The acquisition of this biotech company, which specializes in protein engineering, strengthens our biological research expertise.
The Oncology business unit saw sales expand by 5.9 percent to €215 million (Q3 2007: €203 million). On a currency-adjusted basis the increase came to 9.4 percent, boosted by strong growth in sales of Nexavar® (Fx adj. +62.9 percent), which more than offset the sales decline in certain other products. In July 2008 the Chinese State Food and Drug Administration approved Nexavar® for the treatment of inoperable or metastasizing forms of liver cancer.
Sales from our Dermatology business (Intendis) in the third quarter were level with the prior-year quarter at €60 million, rising by 1.3 percent on a currency-adjusted basis.
In September 2008 we acquired DIREVO Biotech AG, Cologne, Germany. The acquisition of this biotech company, which specializes in protein engineering, strengthens our biological research expertise.
| Best-Selling Pharmaceutical Products | 3rd Quarter 2007 | 3rd Quarter 2008 | Change | Currency- adjusted Change | First Nine Months 2007 | First Nine Months 2008 | Change | Currency- adjusted Change |
| € million | € million | % | % | € million | € million | % | % | |
| Yasmin®/ YAZ®/ Yasminelle® (Women's Healthcare) | 278 | 308 | +10.8 | +15.1 | 768 | 910 | +18.5 | +26.3 |
| Betaferon®/ Betaseron® (Specialized Therapeutics) | 262 | 291 | +11.1 | +15.2 | 762 | 839 | +10.1 | +15.6 |
| Kogenate® (Hematology/ Cardiology) | 213 | 235 | +10.3 | +14.8 | 624 | 650 | +4.2 | +9.7 |
| Adalat® (Primary Care) | 152 | 148 | -2.6 | +1.8 | 459 | 456 | -0.7 | +3.5 |
| Mirena® (Women's Healthcare) | 96 | 105 | +9.4 | +17.1 | 265 | 335 | +26.4 | +37.4 |
| Avalox®/ Avelox® (Primary Care) | 99 | 101 | +2.0 | +6.3 | 317 | 334 | +5.4 | +11.5 |
| Nexavar® (Oncology) | 76 | 121 | +59.2 | +62.9 | 183 | 330 | +80.3 | +89.0 |
| Levitra® (Primary Care) | 85 | 82 | -3.5 | +0.9 | 250 | 248 | -0.8 | +5.5 |
| Cipro®/ Ciprobay® (Primary Care) | 96 | 84 | -12.5 | -7.6 | 297 | 242 | -18.5 | -14.7 |
| Glucobay® (Primary Care) | 74 | 75 | +1.4 | +1.2 | 225 | 229 | +1.8 | +4.4 |
| Aspirin Cardio® (Primary Care) | 59 | 67 | +13.6 | +15.8 | 170 | 198 | +16.5 | +20.0 |
| Ultravist® (Diagnostic Imaging) | 59 | 61 | +3.4 | +10.1 | 178 | 194 | +9.0 | +15.4 |
| Magnevist® (Diagnostic Imaging) | 77 | 61 | -20.8 | -16.3 | 231 | 180 | -22.1 | -16.6 |
| Iopamiron® (Diagnostic Imaging) | 48 | 47 | -2.1 | -2.3 | 152 | 138 | -9.2 | -8.9 |
| Diane® (Women's Healthcare) | 41 | 42 | +2.4 | +4.0 | 129 | 124 | -3.9 | -2.0 |
| Total | 1,715 | 1,828 | +6.6 | +10.7 | 5,010 | 5,407 | +7.9 | +13.6 |
| Proportion of Pharmaceuticals sales | 67% | 69% | 66% | 69% |
Third-quarter EBITDA before special items of the Pharmaceuticals segment rose by 3.2 percent to €738 million (Q3 2007: €715 million). The strong performance of the business and the synergies already realized from the integration of Schering AG, Germany, contributed to earnings growth. These factors were partially offset by higher marketing costs, mainly for Nexavar®, Xarelto®, and the expansion of our Primary Care business in China. EBIT before special items came in at €461 million, up 5.3 percent from the prior-year figure of €438 million. The main components of the €155 million in special charges were €99 million related to the acquisition and integration of Schering AG, Germany, and €52 million in connection with the market withdrawal of Vasovist®. EBIT jumped by 81.1 percent to €306 million (Q3 2007: €169 million).
Sales of the Pharmaceuticals segment in the first nine months of 2008 rose by 2.5 percent to €7,836 million (9M 2007: €7,648 million). This corresponds to a currency- and portfolio-adjusted 7.2 percent increase, for which the gratifying development of Nexavar® (Fx adj. +89.0 percent), Mirena® (Fx adj. +37.4 percent), Yasmin®/YAZ®/Yasminelle® (Fx adj. +26.3 percent) and Aspirin Cardio® (Fx adj. +20.0 percent) was largely responsible. The gains for these products were partially offset by declining sales of Magnevist® (Fx adj. –16.6 percent), Cipro®/Ciprobay® (Fx adj. –14.7 percent) and Trasylol®. EBITDA before special items rose to €2,276 million (9M 2007: €2,137 million), while EBIT before special items was up by €53 million to €1,327 million. After special items totaling minus €346 million, EBIT improved by 49.3 percent to €981 million (9M 2007: €657 million).
Sales of the Pharmaceuticals segment in the first nine months of 2008 rose by 2.5 percent to €7,836 million (9M 2007: €7,648 million). This corresponds to a currency- and portfolio-adjusted 7.2 percent increase, for which the gratifying development of Nexavar® (Fx adj. +89.0 percent), Mirena® (Fx adj. +37.4 percent), Yasmin®/YAZ®/Yasminelle® (Fx adj. +26.3 percent) and Aspirin Cardio® (Fx adj. +20.0 percent) was largely responsible. The gains for these products were partially offset by declining sales of Magnevist® (Fx adj. –16.6 percent), Cipro®/Ciprobay® (Fx adj. –14.7 percent) and Trasylol®. EBITDA before special items rose to €2,276 million (9M 2007: €2,137 million), while EBIT before special items was up by €53 million to €1,327 million. After special items totaling minus €346 million, EBIT improved by 49.3 percent to €981 million (9M 2007: €657 million).
Consumer Health
Sales of the Consumer Health segment came in at €1,164 million in the third quarter of 2008, up 4.9 percent from €1,110 million in the prior-year period. Adjusted for currency and portfolio effects, business expanded by 6.7 percent, with all divisions contributing to this increase.
In the Consumer Care Division, sales advanced by 6.0 percent to €693 million (Q3 2007: €654 million). The increase came in part from our business with the calcium supplement Citracal® acquired in October 2007, the Sagmel business acquired in Europe in June 2008 and, since September 2008, the Topsun business acquired in China. Sales rose by 4.8 percent on a currency- and portfolio-adjusted basis. Bepanthen®/Bepanthol® (Fx adj. +21.4 percent) and Canesten® (Fx adj. +11.4 percent) posted particularly strong gains.
Sales of the Diabetes Care Division rose by 5.9 percent in the third quarter of 2008, to €233 million (Q3 2007: €220 million). On a currency-adjusted basis, business expanded by 11.0 percent. Sales of our Contour® line of blood glucose monitoring systems moved ahead to €128 million (Fx adj. +19.1 percent), driven by growth in North America and Europe. Sales of Breeze® also climbed strongly (Fx adj. +37.8 percent). This increase was partly related to a price increase in the United States announced for October. Sales of our older Elite® systems continued to decline in the third quarter to €28 million (Fx adj. -28.7 percent).
Sales of the Animal Health Division edged up 0.8 percent to €238 million (Q3 2007: €236 million). On a currency-adjusted basis, sales rose by 8.1 percent. We were especially pleased with the performance of the Advantage® product line (Fx adj. +19.0 percent).
The Consumer Health segment saw third-quarter EBITDA before special items improve to €280 million (Q3 2007: €238 million), due mainly to business expansion in all divisions. Earnings in the prior-year period were diminished by charges of €15 million to modernize the IT infrastructure of Diabetes Care in North America. EBIT before special items in the third quarter of 2008 increased by 17.5 percent to €242 million (Q3 2007: €206 million). After special charges of €5 million related to litigation, EBIT climbed by 15.0 percent to €237 million (Q3 2007: €206 million).
Sales in the first three quarters of 2008 improved by 2.1 percent to €3,431 million (9M 2007: €3,359 million). Adjusted for currency and portfolio effects, business expanded by 6.8 percent. EBITDA before special items of the Consumer Health segment advanced by €53 million year-on-year to €786 million. EBIT before special items grew by 6.9 percent to €678 million (9M 2007: €634 million). After special items of minus €40 million, EBIT rose by €4 million to €638 million (9M: €634 million).
In the Consumer Care Division, sales advanced by 6.0 percent to €693 million (Q3 2007: €654 million). The increase came in part from our business with the calcium supplement Citracal® acquired in October 2007, the Sagmel business acquired in Europe in June 2008 and, since September 2008, the Topsun business acquired in China. Sales rose by 4.8 percent on a currency- and portfolio-adjusted basis. Bepanthen®/Bepanthol® (Fx adj. +21.4 percent) and Canesten® (Fx adj. +11.4 percent) posted particularly strong gains.
Sales of the Diabetes Care Division rose by 5.9 percent in the third quarter of 2008, to €233 million (Q3 2007: €220 million). On a currency-adjusted basis, business expanded by 11.0 percent. Sales of our Contour® line of blood glucose monitoring systems moved ahead to €128 million (Fx adj. +19.1 percent), driven by growth in North America and Europe. Sales of Breeze® also climbed strongly (Fx adj. +37.8 percent). This increase was partly related to a price increase in the United States announced for October. Sales of our older Elite® systems continued to decline in the third quarter to €28 million (Fx adj. -28.7 percent).
Sales of the Animal Health Division edged up 0.8 percent to €238 million (Q3 2007: €236 million). On a currency-adjusted basis, sales rose by 8.1 percent. We were especially pleased with the performance of the Advantage® product line (Fx adj. +19.0 percent).
The Consumer Health segment saw third-quarter EBITDA before special items improve to €280 million (Q3 2007: €238 million), due mainly to business expansion in all divisions. Earnings in the prior-year period were diminished by charges of €15 million to modernize the IT infrastructure of Diabetes Care in North America. EBIT before special items in the third quarter of 2008 increased by 17.5 percent to €242 million (Q3 2007: €206 million). After special charges of €5 million related to litigation, EBIT climbed by 15.0 percent to €237 million (Q3 2007: €206 million).
Sales in the first three quarters of 2008 improved by 2.1 percent to €3,431 million (9M 2007: €3,359 million). Adjusted for currency and portfolio effects, business expanded by 6.8 percent. EBITDA before special items of the Consumer Health segment advanced by €53 million year-on-year to €786 million. EBIT before special items grew by 6.9 percent to €678 million (9M 2007: €634 million). After special items of minus €40 million, EBIT rose by €4 million to €638 million (9M: €634 million).
| Consumer Health | 3rd Quarter 2007 | 3rd Quarter 2008 | Change | First Nine Months 2007 | First Nine Months 2008 | Change |
| € million | € million | % | € million | € million | % | |
| Sales | 1,110 | 1,164 | +4.9 | 3,359 | 3,431 | +2.1 |
| Consumer Care | 654 | 693 | +6.0 | 1,937 | 1,989 | +2.7 |
| Diabetes Care | 220 | 233 | +5.9 | 690 | 709 | +2.8 |
| Animal Health | 236 | 238 | +0.8 | 732 | 733 | +0.1 |
| Sales by Region | ||||||
| Europe | 436 | 493 | +13.1 | 1,344 | 1,457 | +8.4 |
| North America | 382 | 379 | -0.8 | 1,170 | 1,096 | -6.3 |
| Asia/Pacific | 95 | 102 | +7.4 | 267 | 295 | +10.5 |
| Latin America/Africa/ Middle East | 197 | 190 | -3.6 | 578 | 583 | +0.9 |
| EBITDA1 | 238 | 275 | +15.5 | 733 | 746 | +1.8 |
| Special items | 0 | (5) | 0 | (40) | ||
| EBITDA before special items2 | 238 | 280 | +17.6 | 733 | 786 | +7.2 |
| EBITDA margin before special items | 21.4% | 24.1% | 21.8% | 22.9% | ||
| EBIT1 | 206 | 237 | +15.0 | 634 | 638 | +0.6 |
| Special items | 0 | (5) | 0 | (40) | ||
| EBIT before special items2 | 206 | 242 | +17.5 | 634 | 678 | +6.9 |
| Gross cash flow1 | 189 | 213 | +12.7 | 520 | 565 | +8.7 |
| Net cash flow1 | 220 | 183 | -16.8 | 406 | 421 | +3.7 |
1 for definition see Bayer Group Key Data.
2 for definition see also Calculation of EBIT(DA) Before Special Items.
2 for definition see also Calculation of EBIT(DA) Before Special Items.
| Best-Selling Consumer Health Products | 3rd Quarter 2007 | 3rd Quarter 2008 | Change | Currency- adjusted change | First Nine Months 2007 | First Nine Months 2008 | Change | Currency- adjusted change |
| € million | € million | % | % | € million | € million | % | % | |
| Contour® 1 (Diabetes Care) | 112 | 128 | +14.3 | +19.1 | 347 | 401 | +15.6 | +22.9 |
| Aspirin® 2 (Consumer Care) | 112 | 105 | -6.3 | -3.7 | 332 | 324 | -2.4 | +2.6 |
| Advantage®- product line (Animal Health) | 76 | 85 | +11.8 | +19.0 | 256 | 262 | +2.3 | +11.2 |
| Aleve®/Naproxen (Consumer Care) | 53 | 48 | -9.4 | -5.8 | 177 | 153 | -13.6 | -4.2 |
| Canesten® (Consumer Care) | 48 | 51 | +6.3 | +11.4 | 138 | 152 | +10.1 | +16.6 |
| Bepanthen®/Bepanthol® (Consumer Care) | 34 | 41 | +20.6 | +21.4 | 110 | 132 | +20.0 | +20.8 |
| Breeze® 1 (Diabetes Care) | 31 | 40 | +29.0 | +37.8 | 112 | 108 | -3.6 | +3.6 |
| Baytril® (Animal Health) | 38 | 38 | 0.0 | +5.6 | 111 | 107 | -3.6 | +2.5 |
| Supradyn® (Consumer Care) | 36 | 35 | -2.8 | +0.4 | 101 | 103 | +2.0 | +4.9 |
| One-A-Day® (Consumer Care) | 37 | 35 | -5.4 | +2.6 | 97 | 92 | -5.2 | +6.4 |
| Total | 577 | 606 | +5.0 | +9.8 | 1,781 | 1,834 | +3.0 | +9.7 |
| Proportion of Consumer Health sales | 52% | 52% | 53% | 53% |
1 previously included with the Ascensia® product family.
2 Total Aspirin® Q3 sales = €172 million (Q3 2007: €171 million), 9M sales = €522 million (9M 2007: €502 million) including Aspirin Cardio®, which is reflected in sales of the Pharmaceuticals segment
2 Total Aspirin® Q3 sales = €172 million (Q3 2007: €171 million), 9M sales = €522 million (9M 2007: €502 million) including Aspirin Cardio®, which is reflected in sales of the Pharmaceuticals segment
Bookmark this page
E-mail this page
Advanced Search
